Core Viewpoint - Nykredit Realkredit A/S has published prepayment data as of March 6, 2026, in compliance with the Danish Capital Markets Act [1]. Group 1 - The prepayment data is available in an attached file and will also be distributed through Nasdaq Copenhagen [1]. - Data on Nykredit and Totalkredit bonds can be accessed by ISIN code in Excel format on the Nykredit investor relations website [1]. Group 2 - For further inquiries regarding the data format and contents, stakeholders can refer to the Nasdaq website or contact Morten Bækmand Nielsen, Head of Investor Relations [2].

Core Viewpoint - More than 70% of UK cloud providers support urgent regulatory intervention in the cloud market to address competition concerns, particularly regarding dominant players like Microsoft and Amazon Web Services (AWS) [1][2]. Group 1: Survey Findings - 71.2% of cloud providers view regulatory action as urgent or extremely urgent, fearing that without intervention, dominant providers will further entrench their market positions [2]. - 82% of cloud providers have faced barriers when competing with larger players, including restrictive software licensing, bundling, interoperability challenges, and committed-spend discounts [3]. - Nearly 65% of cloud customers believe that rapid regulatory measures to enhance competition and reduce vendor lock-in are very important for their organizations [3]. Group 2: Impact of Delayed Regulation - 68% of cloud buyers predict that delayed regulation will lead to increased costs, while nearly two-thirds expect reduced organizational flexibility [4]. - Significant switching costs and limited interoperability are major factors hindering customers from transferring workloads or adopting multi-cloud strategies, reinforcing reliance on AWS and Microsoft [5]. Group 3: Industry Concerns - Industry representatives warn that delays in regulatory intervention by the Competition and Markets Authority (CMA) may result in greater market concentration, making future regulatory actions less effective and more costly [5]. - The Open Cloud Coalition, which commissioned the survey, advocates for a diverse and competitive cloud industry, emphasizing principles such as openness, competition, security, and reliability [6]. Group 4: Expert Commentary - Nicky Stewart, a senior adviser for the Open Cloud Coalition, stated that the cloud market is not functioning properly and that without urgent intervention, dominant providers will continue to lock customers in, harming competition and innovation [7].

Core Insights - The article highlights Rida Morwa's extensive experience in investment and commercial banking, emphasizing his focus on high-yield investment strategies since 1991 [1] - The Investing Group High Dividend Opportunities aims for a targeted safe yield of over 9%, offering various investment features and community support [1] Group 1 - Rida Morwa has over 35 years of experience in advising clients on high-yield investment strategies [1] - The service includes a model portfolio with buy/sell alerts, preferred and baby bond portfolios for conservative investors, and regular market updates [1] - The philosophy of the service emphasizes community and education, promoting the idea that investors should not invest alone [1] Group 2 - The article mentions that recommendations are closely monitored, with Buy and Sell alerts issued exclusively to members [3] - Contributors to the service include Philip Mause and Hidden Opportunities, indicating a collaborative approach to investment advice [3]

Core Insights - TE Connectivity has exceeded several of its 2025 corporate responsibility goals, demonstrating significant progress in sustainability, safety, and inclusivity [1] Sustainability Achievements - The company has surpassed its goal of sourcing 80% of its electricity from renewable sources by achieving 87% [1] - A solar energy system in Lamphun, Thailand, generates 1.2 million kWh annually, accounting for approximately 15% of the site's energy use and reducing emissions by about 520 tons per year [1] - TE has reduced water withdrawal for targeted water-stressed sites by 22%, exceeding its goal of 15% [1] - The amount of hazardous waste disposed has been reduced by 66%, surpassing the goal of 15% [1] Safety Improvements - TE Connectivity has improved worker safety, achieving a Total Reportable Incident Rate of 0.06, which is better than the goal of 0.12 [1] Future Goals - The company aims to reduce Scope 3 greenhouse gas emissions by 30% by 2032, having already achieved a 17% reduction since 2022 [1] - TE has doubled the number of zero waste to landfill sites to 56 and has diverted 93% of its waste from landfills and incinerators, approaching its goal of 98% [1]

Core Viewpoint - Amazon Pharmacy has expanded access to the Zepbound® KwikPen®, a multi-dose injectable treatment for weight management developed by Eli Lilly, providing a more convenient medication delivery option for patients [1] Group 1: Company Developments - Amazon Pharmacy is a full-service digital pharmacy that delivers medications directly to customers' homes [1] - The Zepbound® KwikPen® is designed to deliver a full month of medication in a single device, reducing the number of single-dose devices required for patients [1] Group 2: Industry Impact - The introduction of the Zepbound® KwikPen® through Amazon Pharmacy reflects a growing trend in the pharmaceutical industry towards more convenient and efficient medication delivery systems [1]

Core Viewpoint - Bitcoin Bancorp will present at the NIBA's 152nd Investment Conference on March 11-12, 2026, to engage with the investment community and discuss its strategy for expanding its Bitcoin ATM network and digital asset infrastructure [2][4][5]. Company Overview - Bitcoin Bancorp, Inc. is a diversified digital asset infrastructure and Banking-as-a-Service (BaaS) company focused on expanding secure retail access to cryptocurrency through licensed Bitcoin ATM networks and blockchain technologies [7]. - The company holds foundational patents for Bitcoin ATMs and operates a growing network of compliant retail access points for digital assets [7]. Conference Participation - Executives from Bitcoin Bancorp will deliver a corporate presentation and hold one-on-one meetings with investors and members of the digital asset community during the NIBA conference [4][5]. - The conference provides an opportunity for the company to highlight its strategy for scaling secure and compliant retail access points for digital assets [5]. Strategic Focus - Bitcoin Bancorp aims to pair access to digital assets with strong fraud-prevention and compliance controls, ensuring a safe and transparent in-store experience for consumers [5]. - The company is aligning its retail rollout strategy with recognized convenience-store chains, which will be a focal point during the conference [5]. Long-term Growth Potential - The company is positioned for long-term growth within the digital asset infrastructure sector, particularly through its next-generation licensed Bitcoin ATMs [6].

Core Insights - The article discusses the psychological impact of anxiety, emphasizing that the "what-if" cycle often exacerbates fears rather than the initial source of anxiety itself [1] Group 1 - Leo Nelissen is identified as a long-term investor and macro-focused strategist, specializing in dividend growth and high-quality compounders [1] - The investment strategy combines macro analysis with bottom-up stock research to identify businesses with strong cash-flow potential [1] - Nelissen also contributes to Main Street Alpha, providing in-depth research and actionable investment ideas for long-term investors [1]

Core Insights - Abercrombie & Fitch reported a decline in net income to $515 million from $574 million year-over-year, while operating income also decreased to $699 million from $741 million [1] - Despite an increase in sales to $5.2 billion from $4.9 billion, costs rose to $2 billion from $1.8 billion, impacting profitability [1] - The fourth quarter saw net income drop to $174.7 million from $189.7 million, with operating income falling to $236 million from $256 million, although sales increased to $1.7 billion from $1.6 billion [1] Financial Performance - The company achieved record fourth quarter net sales, marking the thirteenth consecutive quarter of growth, with operating margin and earnings per share meeting high expectations [2] - For fiscal 2025, Abercrombie & Fitch reported a 6% growth in net sales and maintained double-digit operating margins for the third consecutive year, supported by $619 million in operating cash flow [3] - The company repurchased 5.4 million shares, representing 11% of shares outstanding at the beginning of the year, emphasizing its commitment to long-term value creation [3] Future Outlook - Abercrombie & Fitch entered fiscal 2026 with a strong foundation, aiming for net sales growth of 1%-3% for Q1 and 3%-5% for the full year, alongside another year of double-digit operating margin and earnings per share growth [4] - The company expects an operating margin of around 7% for Q4 and between 12%-12.5% for the full year, with net income per diluted share projected in the range of $1.20-$1.30 for Q4 and $10.20-$11.00 for the full year [5]

Core Insights - InMed Pharmaceuticals is advancing its Alzheimer's disease program, particularly focusing on the INM-901 drug candidate, with plans to initiate a Phase 1 clinical trial in 2027 [1][3][10] INM-901 Program Outlook - INM-901 is a proprietary, orally bioavailable small molecule drug candidate that targets neuroinflammation in Alzheimer's disease by acting as a CB1/CB2 signaling agonist [3][4] - The company has generated preclinical evidence showing that INM-901 reduces inflammatory biomarkers and neurodegenerative markers, indicating its potential therapeutic effects [4][9] - The program aims to clarify its focus on neuroinflammation, which is believed to be a primary driver of Alzheimer's progression, rather than a secondary effect [4][5] Development Plans for 2026 - The company plans to conduct a pre-IND meeting with the FDA in Q3 2026 to discuss the INM-901 program, which is seen as a critical milestone [3][10] - Continued development of INM-089, a candidate for dry age-related macular degeneration, is also planned, with a pre-IND meeting targeted for Q4 2026 [6][10] - The company is executing IND-enabling pharmacology and toxicology studies, with a focus on advancing drug substance and product development [9][10] Scientific and Operational Progress - Significant progress has been made in understanding the anti-neuroinflammatory effects of INM-901, with data supporting its multifactorial mechanism of action [2][5] - Preclinical studies have shown improvements in cognitive function and neuronal regeneration, reinforcing the drug's potential efficacy [9][10] - The company is also working on optimizing drug formulation and scaling up manufacturing processes to support future studies [9][10]

Core Viewpoint - ImmunityBio has resubmitted its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors, following FDA's request for additional data [1][2][11] Group 1: FDA Interaction and Resubmission - The resubmission of the sBLA follows ongoing discussions with the FDA that began in January 2026, where the FDA requested additional data to support the review without requiring new clinical trials [2][11] - The FDA acknowledged receipt of the resubmitted sBLA, which includes updated long-term follow-up data for patients with papillary-only NMIBC [2][11] Group 2: Clinical Data and Efficacy - Long-term results from the QUILT 3.032 Phase 2/3 trial demonstrated a 12-month disease-free survival (DFS) rate of 58.2% in 80 patients with high-grade papillary-only NMIBC [5] - The study reported a 96.0% disease-specific survival (DSS) rate at 36 months and a progression-free survival (PFS) of 94.9% at 12 months, indicating durable prevention of progression to muscle-invasive disease [5] - Cystectomy-free survival was reported at 92.2% at 12 months and 81.8% at 36 months, suggesting that over 80% of patients avoided radical cystectomy through three years of follow-up [5] Group 3: Mechanism of Action and Regulatory Insights - ANKTIVA's mechanism of action as an IL-15 superagonist was affirmed by the FDA's previous approval in 2024 for BCG-unresponsive NMIBC with carcinoma in situ [3] - The recent approval by the Saudi Food and Drug Authority (SFDA) for ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC) highlights its potential in addressing unmet medical needs in this patient population [3][4] Group 4: Company Overview and Future Plans - ImmunityBio focuses on developing next-generation immunotherapies that activate the immune system to provide durable protection against cancer and infectious diseases [12] - The company plans to present clinical data supporting the SFDA approval and continue discussions with the FDA regarding treatment options for patients with metastatic NSCLC who have exhausted current standards of care [4][12]